Usefulness of Global Coagulation Tests, Thrombin Generation and Viscoelastic Tests for Assessing the Bleeding Phenotype in Rare Coagulation Factor Deficiencies

Abstract

Inherited deficiencies of coagulation factors are rare and exhibit variable associations with severe bleeding phenotypes. Although conventional hemostatic assays serve as useful screening tools, they often fail to accurately predict clinical bleeding severity. Disease management is further complicated by poor correlation between residual factor levels and the overall symptom severity in affected patients and limited clinical experience. In this review, we evaluate the utility of global coagulation tests, such as the thrombin generation assay, plasmin generation assay (PGA), and rotational thromboelastometry (ROTEM), in assessing the severity of rare coagulation factor deficiencies and their clinical manifestations.

Overall, thrombin generation, plasmin generation, and ROTEM were impaired in most rare coagulation factor deficiencies. Furthermore, significantly reduced coagulation factor activity and consequently decreased thrombin generation potential correlated with the clinical bleeding severity in deficiencies of prothrombin and factors V, VII, X, and XI. PGA was significantly impaired in fibrinogen and prothrombin deficiency and variably reduced in FV- and FX-deficient patients, but did not correlate with the presence or severity of bleeding manifestations. Lastly, ROTEM parameters were able to discriminate between asymptomatic FX-, FXI-, and fibrinogen-deficient patients and those with a history of bleeding.

Although these studies are mostly limited to small sample sizes and prospective data are lacking, the available literature suggests that TGA, PGA, and ROTEM may be useful in stratifying patients according to their overall bleeding severity, as well as their risk of major bleeding complications in some of the rare coagulation factor deficiencies.

Keywords

inherited bleeding disorders - coagulation factor deficiency - thrombin generation assay - rotational thromboelastometry - routine hemostatic tests

Support for Attending Meetings and/or Travel

Novo Nordisk, travel support to GTH 2023.

Roche, travel support to ASH 2023.

Sobi, travel support to EHA 2023.

Pfizer, travel support to ISTH 2023.

Consulting Fees

Novartis, SOBI, Amgen, Sanofi, CSL Behring.

Grant

Prof. Heimburger Award, research grant (to institution).

EHA Research Mobility Grant, research grant (to institution).

Medical-scientific fund of the mayor of the federal capital Vienna, research grant (to institution).

Research support from Novartis, SOBI, Amgen, Sanofi, and CSL Behring.

Invited Review for the “Diagnosis and treatment of rare congenital bleeding disorders” themed issue.

Publikationsverlauf

Eingereicht: 27. März 2025

Angenommen: 18. August 2025

Artikel online veröffentlicht:
15. Oktober 2025

• References

• 1 Rajmil L, Perestelo-Pérez L, Herdman M. Quality of life and rare diseases. In: Posada De La Paz M, Groft SC. eds. Rare Diseases Epidemiology. Vol 686. Advances in Experimental Medicine and Biology. Springer Netherlands: 2010: 251-272
• 2 Peyvandi F, Di Michele D, Bolton-Maggs PHB, Lee CA, Tripodi A, Srivastava A. Project on Consensus Definitions in Rare Bleeeding Disorders of the Factor VIII/Factor IX Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Classification of rare bleeding disorders (RBDs) based on the association between coagulant factor activity and clinical bleeding severity. J Thromb Haemost 2012; 10 (09) 1938-1943
• 3 Palla R, Peyvandi F, Shapiro AD. Rare bleeding disorders: diagnosis and treatment. Blood 2015; 125 (13) 2052-2061
• 4 Sinauridze EI, Vuimo TA, Tarandovskiy ID. et al. Thrombodynamics, a new global coagulation test: measurement of heparin efficiency. Talanta 2018; 180: 282-291
• 5 Van Geffen M, Menegatti M, Loof A. et al. Retrospective evaluation of bleeding tendency and simultaneous thrombin and plasmin generation in patients with rare bleeding disorders. Haemophilia 2012; 18 (04) 630-638
• 6 Pasca S, Santoro C, Ambaglio C. et al. Comparison among three different bleeding scores and the thrombin generation assay to assess the different hemorrhagic phenotypes in patients with FVII deficiency. Bleeding Thromb Vasc Biol 2022 1. 02
• 7 Verhagen MJA, van Heerde WL, van der Bom JG. et al. In patients with hemophilia, a decreased thrombin generation profile is associated with a severe bleeding phenotype. Res Pract Thromb Haemost 2023; 7 (02) 100062
• 8 Valke LLFG, Bukkems LH, Barteling W. et al. Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: combining thrombin and plasmin generation. J Thromb Haemost 2020; 18 (12) 3222-3231
• 9 Gupta D, Arya V, Dass J. et al. Assessment of the phenotypic severity of hemophilia A: using rotational thromboelastometry (ROTEM) and APTT-clot waveform analysis. Blood Res 2024; 59 (01) 19
• 10 Tarandovskiy ID, Balandina AN, Kopylov KG. et al. Investigation of the phenotype heterogeneity in severe hemophilia A using thromboelastography, thrombin generation, and thrombodynamics. Thromb Res 2013; 131 (06) e274-e280
• 11 Dorgalaleh A, Tabibian S, Shams M, Tavasoli B, Gheidishahran M, Shamsizadeh M. Laboratory diagnosis of factor XIII deficiency in developing countries: an Iranian experience. Lab Med 2016; 47 (03) 220-226
• 12 Salloum-Asfar S, de la Morena-Barrio ME, Esteban J. et al. Assessment of two contact activation reagents for the diagnosis of congenital factor XI deficiency. Thromb Res 2018; 163: 64-70
• 13 Rejtő J, Königsbrügge O, Grilz E. et al. Influence of blood group, von Willebrand factor levels, and age on factor VIII levels in non-severe haemophilia A. J Thromb Haemost 2020; 18 (05) 1081-1086
• 14 Peyvandi F, Palla R, Menegatti M. et al; European Network of Rare Bleeding Disorders Group. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J Thromb Haemost 2012; 10 (04) 615-621
• 15 Simurda T, Asselta R, Zolkova J. et al. Congenital afibrinogenemia and hypofibrinogenemia: laboratory and genetic testing in rare bleeding disorders with life-threatening clinical manifestations and challenging management. Diagnostics (Basel) 2021; 11 (11) 2140
• 16 Hariharan G, Ramachandran S, Parapurath R. Congenital afibrinogenemia presenting as antenatal intracranial bleed: a case report. Ital J Pediatr 2010; 36: 1
• 17 de Moerloose P, Casini A, Neerman-Arbez M. Congenital fibrinogen disorders: an update. Semin Thromb Hemost 2013; 39 (06) 585-595
• 18 Naz A, Biswas A, Khan TN. et al. Identification of novel mutations in congenital afibrinogenemia patients and molecular modeling of missense mutations in Pakistani population. Thromb J 2017; 15 (01) 24
• 19 Casini A, Brungs T, Lavenu-Bombled C, Vilar R, Neerman-Arbez M, de Moerloose P. Genetics, diagnosis and clinical features of congenital hypodysfibrinogenemia: a systematic literature review and report of a novel mutation. J Thromb Haemost 2017; 15 (05) 876-888
• 20 Cunningham MT, Brandt JT, Laposata M, Olson JD. Laboratory diagnosis of dysfibrinogenemia. Arch Pathol Lab Med 2002; 126 (04) 499-505
• 21 Lancellotti S, De Cristofaro R. Congenital prothrombin deficiency. Semin Thromb Hemost 2009; 35 (04) 367-381
• 22 Huang JN, Koerper MA. Factor V deficiency: a concise review. Haemophilia 2008; 14 (06) 1164-1169
• 23 Stoj KM, Pierro J. Factor V Deficiency. In: StatPearls. StatPearls Publishing; 2024. Accessed December 16, 2024 at: http://www.ncbi.nlm.nih.gov/books/NBK580494/
• 24 Ouerradi N, Ayad G, Elouali A, Babakhouya A, Rkain M. A serendipitous finding of coagulation factor VII deficiency in two asymptomatic patients. Cureus 2024; 16 (08) e68133
• 25 Perry DJ. Factor VII deficiency. Br J Haematol 2002; 118 (03) 689-700
• 26 Iwaniec T, Zdziarska J, Musiał J, Sanak M. A Retrospective analysis of clinical and laboratory data of patients with factor VII deficiency: a single centre experience. Hamostaseologie 2019; 39 (04) 368-376
• 27 Mariani G, Herrmann FH, Dolce A. et al; International Factor VII Deficiency Study Group. Clinical phenotypes and factor VII genotype in congenital factor VII deficiency. Thromb Haemost 2005; 93 (03) 481-487
• 28 Napolitano M, Siragusa S, Mariani G. Factor VII deficiency: clinical phenotype, genotype and therapy. J Clin Med 2017; 6 (04) 38
• 29 Peyvandi F, Auerswald G, Austin SK. et al. Diagnosis, therapeutic advances, and key recommendations for the management of factor X deficiency. Blood Rev 2021; 50: 100833
• 30 Bolton-Maggs PHB, Perry DJ, Chalmers EA. et al. The rare coagulation disorders—review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia 2004; 10 (05) 593-628
• 31 Zhang X, Lewandowska M, Aldridge M, Iglay K, Wolford E, Shapiro A. Global epidemiology of factor XI deficiency: a targeted review of the literature and foundation reports. Haemophilia 2023; 29 (02) 423-434
• 32 Lewandowska MD, Connors JM. Factor XI deficiency. Hematol Oncol Clin North Am 2021; 35 (06) 1157-1169
• 33 Lorand L, Losowsky MS, Miloszewski KJ. Human factor XIII: fibrin-stabilizing factor. Prog Hemost Thromb 1980; 5: 245-290
• 34 Brummel KE, Paradis SG, Butenas S, Mann KG. Thrombin functions during tissue factor-induced blood coagulation. Blood 2002; 100 (01) 148-152
• 35 Tripodi A. Thrombin generation: a global coagulation procedure to investigate hypo- and hyper-coagulability. Haematologica 2020; 105 (09) 2196-2199
• 36 Al Dieri R, Peyvandi F, Santagostino E. et al. The thrombogram in rare inherited coagulation disorders: its relation to clinical bleeding. Thromb Haemost 2002; 88 (04) 576-582
• 37 Young GA, Carmona R, Cano Garcia V. Thromboelastography and thrombin generation assay in inherited afibrinogenemia. Haemophilia 2018; 24 (06) e410-e416
• 38 Duckers C, Simioni P, Spiezia L. et al. Residual platelet factor V ensures thrombin generation in patients with severe congenital factor V deficiency and mild bleeding symptoms. Blood 2010; 115 (04) 879-886
• 39 Zavyalova E, Kopylov A. Exploring potential anticoagulant drug formulations using thrombin generation test. Biochem Biophys Rep 2015; 5: 111-119
• 40 Hemker HC, Giesen P, Al Dieri R. et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33 (01) 4-15
• 41 Livnat T, Shenkman B, Martinowitz U. et al. The impact of thrombin generation and rotation thromboelastometry on assessment of severity of factor XI deficiency. Thromb Res 2015; 136 (02) 465-473
• 42 Pitkänen HH, Jouppila A, Lemponen M, Ilmakunnas M, Ahonen J, Lassila R. Factor XIII deficiency enhances thrombin generation due to impaired fibrin polymerization—an effect corrected by factor XIII replacement. Thromb Res 2017; 149: 56-61
• 43 van Geffen M, Loof A, Lap P. et al. A novel hemostasis assay for the simultaneous measurement of coagulation and fibrinolysis. Hematology 2011; 16 (06) 327-336
• 44 Gidley GN, Holle LA, Burthem J, Bolton-Maggs PHB, Lin FC, Wolberg AS. Abnormal plasma clot formation and fibrinolysis reveal bleeding tendency in patients with partial factor XI deficiency. Blood Adv 2018; 2 (10) 1076-1088
• 45 Hartmann J, Hermelin D, Levy JH. Viscoelastic testing: an illustrated review of technology and clinical applications. Res Pract Thromb Haemost 2022; 7 (01) 100031
• 46 Drotarova M, Zolkova J, Belakova KM. et al. Basic principles of rotational thromboelastometry (ROTEM^®) and the role of ROTEM-guided fibrinogen replacement therapy in the management of coagulopathies. Diagnostics (Basel) 2023; 13 (20) 3219
• 47 Bainbridge FJ, Sinha R, Tocchetti R. et al. Introduction of point-of-care ROTEM testing in the emergency department of an Australian level 1 trauma centre and its effect on blood product use. Emerg Med Australas 2021; 33 (05) 893-899
• 48 Crochemore T, Corrêa TD, Lance MD. et al. Thromboelastometry profile in critically ill patients: a single-center, retrospective, observational study. PLoS One 2018; 13 (02) e0192965
• 49 Ramiz S, Hartmann J, Young G, Escobar MA, Chitlur M. Clinical utility of viscoelastic testing (TEG and ROTEM analyzers) in the management of old and new therapies for hemophilia. Am J Hematol 2019; 94 (02) 249-256
• 50 Simurda T, Zolkova J, Snahnicanova Z. et al. Identification of two novel fibrinogen Bβ chain mutations in two Slovak families with quantitative fibrinogen disorders. Int J Mol Sci 2017; 19 (01) 100
• 51 Szanto T, Lassila R, Lemponen M, Lehtinen E, Neerman-Arbez M, Casini A. Whole blood thromboelastometry by ROTEM and thrombin generation by Genesia according to the genotype and clinical phenotype in congenital fibrinogen disorders. Int J Mol Sci 2021; 22 (05) 2286
• 52 Yamada K, Nakajima Y, Ogiwara K, Sakai T, Fukuda K, Nogami K. ROTEM could be useful for lupus anticoagulant hypoprothrombinemia syndrome. Pediatr Int 2024; 66 (01) e15773
• 53 Spiezia L, Radu C, Campello E. et al. Whole blood rotation thromboelastometry (ROTEM(®)) in nine severe factor V deficient patients and evaluation of the role of intraplatelets factor V. Haemophilia 2012; 18 (03) 463-468
• 54 Yeom RS, Wang XA, Elia E, Yoon U. Severe congenital factor VII deficiency with normal perioperative coagulation profile based on ROTEM analysis in a hepatectomy. Am J Case Rep 2021; 22: e930245
• 55 Knio ZO, Ising MS, Yount KW, Tanaka K, McNeil JS. Undiagnosed factor VII deficiency in cardiac surgery complicated by bleeding: a case report. A A Pract 2023; 17 (09) e01713
• 56 Introna M, Broggi M, Ferroli P. et al. Perioperative ROTEM® evaluation in a patient affected by severe VII factor deficiency undergoing microvascular decompression craniotomy for hemifacial spasm. J Clin Monit Comput 2024; 38 (06) 1431-1435
• 57 Cannata G, Mariotti Zani E, Argentiero A, Caminiti C, Perrone S, Esposito S. TEG^® and ROTEM^® traces: clinical applications of viscoelastic coagulation monitoring in neonatal intensive care unit. Diagnostics (Basel) 2021; 11 (09) 1642
• 58 Theusinger OM, Nürnberg J, Asmis LM, Seifert B, Spahn DR. Rotation thromboelastometry (ROTEM) stability and reproducibility over time. Eur J Cardiothorac Surg 2010; 37 (03) 677-683
• 59 Yen CB, Katz DJ. Management of factor X deficiency for vaginal delivery in a parturient: a case report. A A Pract 2021; 15 (02) e01405
• 60 Crabbe A, McNeil JS, Deshpande SP, Kon Z, Pham SM, Tanaka KA. Therapeutic plasma exchange in heart transplantation: role of coagulation assessment with thromboelastometry. JA Clin Rep 2016; 2 (01) 31
• 61 Pike GN, Cumming AM, Thachil J, Hay CRM, Bolton-Maggs PHB, Burthem J. Evaluation of the use of rotational thromboelastometry in the assessment of FXI deficency. Haemophilia 2017; 23 (03) 449-457
• 62 Bertaggia Calderara D, Zermatten MG, Aliotta A. et al. Tissue factor-independent coagulation correlates with clinical phenotype in factor XI deficiency and replacement therapy. Thromb Haemost 2021; 121 (02) 150-163
• 63 Bedreli S, Sowa JP, Malek S. et al. Rotational thromboelastometry can detect factor XIII deficiency and bleeding diathesis in patients with cirrhosis. Liver Int 2017; 37 (04) 562-568
• 64 Casini A, Undas A, Palla R, Thachil J, de Moerloose P. Subcommittee on Factor XIII and Fibrinogen. Diagnosis and classification of congenital fibrinogen disorders: communication from the SSC of the ISTH. J Thromb Haemost 2018; 16 (09) 1887-1890
• 65 Zhang Y, Zuo X, Teng Y. Women with congenital hypofibrinogenemia/afibrinogenemia: from birth to death. Clin Appl Thromb Hemost 2020; 26: 1076029620912819
• 66 al-Mondhiry H, Ehmann WC. Congenital afibrinogenemia. Am J Hematol 1994; 46 (04) 343-347
• 67 Mansory EM, Bhai P, Stuart A, Laudenbach L, Sadikovic B, Lazo-Langner A. A case of congenital prothrombin deficiency with two concurrent mutations in the prothrombin gene. Res Pract Thromb Haemost 2021; 5 (04) e12510
• 68 Tavasoli B, Zangooie A, Safdari SM. et al. Correlation between phenotype and coagulation factor activity level in rare bleeding disorders: a systematic review. Semin Thromb Hemost 2025; 51 (02) 180-195
• 69 Montgomery RR, Otsuka A, Hathaway WE. Hypoprothrombinemia: case report. Blood 1978; 51 (02) 299-306
• 70 Mohapatra AK, Todaro AM, Castoldi E. Factor V variants in bleeding and thrombosis. Res Pract Thromb Haemost 2024; 8 (01) 102330
• 71 Lak M, Sharifian R, Peyvandi F, Mannucci PM. Symptoms of inherited factor V deficiency in 35 Iranian patients. Br J Haematol 1998; 103 (04) 1067-1069
• 72 Lunghi B, Pinotti M, Maestri I, Batorova A, Bernardi F. Evaluation of factor V mRNA to define the residual factor V expression levels in severe factor V deficiency. Haematologica 2008; 93 (03) 477-478
• 73 Delev D, Pavlova A, Heinz S, Seifried E, Oldenburg J. Factor 5 mutation profile in German patients with homozygous and heterozygous factor V deficiency. Haemophilia 2009; 15 (05) 1143-1153
• 74 Jain S, Donkin J, Frey MJ, Peltier S, Gunawardena S, Cooper DL. Phenotypical variability in congenital FVII deficiency follows the ISTH-SSC severity classification guidelines: a review with illustrative examples from the clinic. J Blood Med 2018; 9: 211-218
• 75 Giansily-Blaizot M, Verdier R, Biron-Adréani C. et al; Study group of FVII deficiency. Analysis of biological phenotypes from 42 patients with inherited factor VII deficiency: can biological tests predict the bleeding risk?. Haematologica 2004; 89 (06) 704-709
• 76 Benlakhal F, Mura T, Schved J-F, Giansily-Blaizot M. French Study Group of Factor VII Deficiency. A retrospective analysis of 157 surgical procedures performed without replacement therapy in 83 unrelated factor VII-deficient patients. J Thromb Haemost 2011; 9 (06) 1149-1156
• 77 Dejhansathit S, Suvannasankha A. Acquired factor X deficiency in patients with primary light chain amyloidosis. J Investig Med High Impact Case Rep 2019; 7: 2324709619832332
• 78 Othman T, Abdelkarim A, Huynh K, Uche A, Lee J. Inherited moderate factor X deficiency presenting as cardiac tamponade. Case Rep Hematol 2019; 2019: 9657516
• 79 Herrmann FH, Auerswald G, Ruiz-Saez A. et al; Greifswald Factor X Deficiency Study Group. Factor X deficiency: clinical manifestation of 102 subjects from Europe and Latin America with mutations in the factor 10 gene. Haemophilia 2006; 12 (05) 479-489
• 80 Jayakrishnan T, Shah D, Mewawalla P. Hemophilia C: a case report with updates on diagnosis and management of a rare bleeding disorder. J Hematol (Brossard) 2019; 8 (03) 144-147
• 81 Sucker C, Geisen C, Litmathe J, Zawislak B. Two cases of factor XI deficiency: use of thrombin generation assays (TGA) to detect a non-bleeding phenotype. Arch Clin Cases 2024; 11 (01) 1-4
• 82 Handa S, Sterpi M, Sacchi De Camargo Correia G. et al. Obstetric and perioperative management of patients with factor XI deficiency: a retrospective observational study. Blood Adv 2023; 7 (10) 1967-1975
• 83 Kravtsov DV, Wu W, Meijers JCM. et al. Dominant factor XI deficiency caused by mutations in the factor XI catalytic domain. Blood 2004; 104 (01) 128-134
• 84 Board PG, Losowsky MS, Miloszewski KJA. Factor XIII: inherited and acquired deficiency. Blood Rev 1993; 7 (04) 229-242
• 85 Gerlach R, Tölle F, Raabe A, Zimmermann M, Siegemund A, Seifert V. Increased risk for postoperative hemorrhage after intracranial surgery in patients with decreased factor XIII activity: implications of a prospective study. Stroke 2002; 33 (06) 1618-1623
• 86 Shetty S, Shelar T, Mirgal D. et al. Rare coagulation factor deficiencies: a countrywide screening data from India. Haemophilia 2014; 20 (04) 575-581
• 87 Karimi M, Bereczky Z, Cohan N, Muszbek L. Factor XIII deficiency. Semin Thromb Hemost 2009; 35 (04) 426-438
• 88 Naderi M, Dorgalaleh A, Alizadeh S. et al. Clinical manifestations and management of life-threatening bleeding in the largest group of patients with severe factor XIII deficiency. Int J Hematol 2014; 100 (05) 443-449